Pfizer's Rheumatoid Arthritis Pill May Benefit Pipeline

Loading player, please wait...

Recommended Videos

  • Info

  • Comments

Nov. 8 (Bloomberg) -- Pfizer Inc.’s experimental pill for rheumatoid arthritis reduced pain and inflammation for 71 percent of patients in a study that may help the company supplant injectable drugs with $12 billion in yearly sales. Bloomberg's Shannon Pettypiece reports. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change